SCOPUS 정보 검색 플랫폼

JAMA Ophthalmology

Volumn 131, Issue 10, 2013, Pages

Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma

(3) Kahana, Alon a Worden, Francis P a Elner, Victor M a

a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN;

AGED; BASAL CELL CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; DIARRHEA; EYE EXAMINATION; FEMALE; HISTOPATHOLOGY; HUMAN; LETTER; MUSCLE SPASM; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBIT CANCER; ORBITAL BASAL CELL CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; BIOPSY; CARCINOMA, BASAL CELL; EYE SURGERY; MALE; ORAL DRUG ADMINISTRATION; ORBITAL NEOPLASMS; PATHOLOGY;

ADMINISTRATION, ORAL; AGED; ANILIDES; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, BASAL CELL; CHEMOTHERAPY, ADJUVANT; HEDGEHOG PROTEINS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; OPHTHALMOLOGIC SURGICAL PROCEDURES; ORBITAL NEOPLASMS; PYRIDINES;

EID: 84885912751 PISSN: 21686165 EISSN: None Source Type: Journal
DOI: 10.1001/jamaophthalmol.2013.4430 Document Type: Letter

Times cited : (40)

References (6)

1
- 16244415185
- Orbital invasion by periocular basal cell carcinoma
- DOI 10.1016/j.ophtha.2004.11.036, PII S0161642004018809
- Leibovitch I, McNab A, Sullivan T, Davis G, Selva D. Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005;112(4):717-723. (Pubitemid 41108876)
- (2005) Ophthalmology , vol.112 , Issue.4 , pp. 717-723
- Leibovitch, I.¹ McNab, A.² Sullivan, T.³ Davis, G.⁴ Selva, D.⁵

2
- 84856015846
- Risk factors for orbital exenteration in periocular basal cell carcinoma
- Iuliano A, Strianese D, Uccello G, Diplomatico A, Tebaldi S, Bonavolontà G. Risk factors for orbital exenteration in periocular basal cell carcinoma. Am J Ophthalmol. 2012;153(2):238-241; e1.
- (2012) Am J Ophthalmol. , vol.153 , Issue.2 , pp. 238-241
- Iuliano, A.¹ Strianese, D.² Uccello, G.³ Diplomatico, A.⁴ Tebaldi, S.⁵ Bonavolontà, G.⁶

3
- 84861857695
- Oral hedgehog-pathway inhibitors for basal-cell carcinoma
- Lear JT. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med. 2012;366(23):2225-2226.
- (2012) N Engl J Med. , vol.366 , Issue.23 , pp. 2225-2226
- Lear, J.T.¹

4
- 84861856844
- Efficacy and safety of vismodegib in advanced basal-cell carcinoma
- Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
- (2012) N Engl J Med. , vol.366 , Issue.23 , pp. 2171-2179
- Sekulic, A.¹ Migden, M.R.² Oro, A.E.³

5
- 84861876867
- Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome
- Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180-2188.
- (2012) N Engl J Med. , vol.366 , Issue.23 , pp. 2180-2188
- Tang, J.Y.¹ MacKay-Wiggan, J.M.² Aszterbaum, M.³

6
- 84885903753
- US Food and Drug Administration Accessed October 16, 2012
- US Food and Drug Administration. Vismodegib. http://www.fda.gov/Drugs/ InformationOnDrugs/ApprovedDrugs/ucm289571.htm. Accessed October 16, 2012.
- Vismodegib

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.